Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by riverrrowon Jun 26, 2024 3:32pm

RE:RE:RE:RE:No share price change in US past two days

I heard it was supposed to close June 28.  If they had the 10 mil lined up beforehand that could happen.  My guess is it closes July 5.  GLTA.
31
Discussion
Comment by Gooseybearon Jun 26, 2024 3:19pm

RE:RE:RE:No share price change in US past two days

Great advice! Until one of the FDA politicians or their family members or friends dies of blacd cancer or GBM they will do a slow roll. Big pharma wants TLTFF to fail as they are greedy SOBs with the ...more  
54
Discussion
Comment by gojotv!on Jun 26, 2024 3:10pm

RE:RE:No share price change in US past two days

"the new compound, nicknamed RuBCG, was able to significantly increase the efficacy of BCG in cancer cell kill versus BCG or RuvidarTM alone, when non-light activated." Luckily ...more  
62
Discussion
Comment by 2b7f6fabon Jun 26, 2024 3:02pm

RE:RE:RE:No share price change in US past two days

Interesting, does it do anything for brain, lung, breast, colon etc?
26
Discussion
Comment by Oilminerdeluxeon Jun 26, 2024 1:27pm

RE:RE:RE:No share price change in US past two days

When is the PP supposed to close? Any date given?
43
Discussion
Comment by Alamir1111on Jun 26, 2024 11:23am

RE:RE:No share price change in US past two days

What I'm really excited about is the potential that the Serum Institute's next generation recombinant BCG is even more potent, more immunogenic, and even, according to them from the phase two ...more  
109
Discussion
Comment by Alamir1111on Jun 26, 2024 11:13am

RE:No share price change in US past two days

The bcg strain that ibrx is using is more potent than mercks own.There are already trials going on in europe. keytruda is already facing challenge due to patent expiry now their bcg is getting ...more  
94
Discussion
Post by Gooseybearon Jun 26, 2024 10:13am

No share price change in US past two days

Very interesting. Stock trading hasn't been stopped has it?
114
Discussion
Comment by wildbird1on Jun 26, 2024 9:25am

RE:RE:RE:RE:RE:3rd quarter

Thanks Eoganacht..excellent post. Although R.White did find unusual the request for more central pathology data, at the same time R.White must have felt relieved and said to himself... Woow!!! That is ...more  
226
Discussion
Comment by Johnandrose22on Jun 26, 2024 6:09am

RE:RE:RE:RE:RE:RE:RE:3rd quarter

Eoganacht....thank you. Your response puts Mr.White's words into wider context. Despite his apparent frustration, the CEO remains very confident. And so do I.
100
Discussion
Comment by Eoganachton Jun 25, 2024 9:58pm

RE:RE:RE:RE:RE:RE:3rd quarter

Hi John - maybe the FDA is just being extra careful with a non-mainstream NMIBC treatment type with a dubious past. Photofrin PDT was approved by HC for NMIBC in 1993 before it was recognized that it ...more  
238
Discussion
Comment by plantraderon Jun 25, 2024 9:24pm

RE:RE:RE:RE:RE:3rd quarter

@eog, Thanks. That is a little bit of potential assurance. But we can't exactly go by what the company thinks, since as RDW said the FDA calls the shots. Hopefully he's right in his ...more  
128
Discussion
Comment by N0taP00pon Jun 25, 2024 8:30pm

RE:RE:RE:RE:RE:RE:3rd quarter

Good insights, Eoganacht.Took a look at LabCorp.com , page titled What Does A central Lab Do?   In this case, if the FDA requested them to take every result and replicate it at one of these ...more  
133
Discussion
Comment by Johnandrose22on Jun 25, 2024 7:20pm

RE:RE:RE:RE:RE:3rd quarter

Thanks, as always, Eoganacht! My question arises from Mr. White's summary of local/central pathology and concordance and the accuracy of one to another.  Mr. White found the "ask" ...more  
173
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250